Advertisement
Advertisement
INDV
Indivior Pharmaceuticals, Inc. Common Stock
30.48
USDSponsored
-0.16
-0.54%
Apr 02, 15:59 UTC -4
Closed
After-Market
30.06
-0.43
-1.41%
INDV Earnings Reports
Positive Surprise Ratio
INDV beat 13 of 20 last estimates.
65%
Next Report
Date of Next Report
Apr 23, 2026
Estimate for Q1 26 (Revenue/ EPS)
$278.09M
/$0.66
Implied change from Q4 25 (Revenue/ EPS)
-22.32%
/-19.51%
Implied change from Q1 25 (Revenue/ EPS)
+4.55%
/+60.98%
Indivior Pharmaceuticals, Inc. Common Stock earnings per share and revenue
On Feb 26, 2026, INDV reported earnings of 0.82 USD per share (EPS) for Q4 25, beating the estimate of 0.68 USD, resulting in a 19.27% surprise. Revenue reached 358.00 million, compared to an expected 311.73 million, with a 14.84% difference. The market reacted with a +0.24% price change (close before vs. close after earnings).
Looking ahead to Q1 26, 5 analysts forecast an EPS of 0.66 USD, with revenue projected to reach 278.09 million USD, implying an decrease of -19.51% EPS, and decrease of -22.32% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Centessa Pharmaceuticals plc - ADR
Report Date
Mar 31, 2026 For Q4 25
Estimate
-$0.38
Actual
-$0.48
Surprise
-23.58%
AleAnna, Inc. Class A Common Stock
Report Date
Mar 30, 2026 For Q4 25
Estimate
-Actual
$0.00
Surprise
-
Lexeo Therapeutics, Inc. Common Stock
Report Date
Mar 30, 2026 For Q4 25
Estimate
-$0.32
Actual
-$0.27
Surprise
+15.84%
Surrozen, Inc. Common
Report Date
Mar 30, 2026 For Q4 25
Estimate
-$1.21
Actual
-Surprise
-
Unicycive Therapeutics, Inc. Common Stock
Report Date
Mar 30, 2026 For Q4 25
Estimate
-$0.48
Actual
-$0.81
Surprise
-69.64%
Galectin Therapeutics Inc.
Report Date
Mar 31, 2026 For Q4 25
Estimate
-$0.10
Actual
-$0.08
Surprise
+21.57%
Cardiol Therapeutics Inc. Class A Common Shares
Report Date
Apr 01, 2026 For Q4 25
Estimate
-$0.08
Actual
-$0.07
Surprise
+14.22%
Actinium Pharmaceuticals, Inc
Report Date
Mar 30, 2026 For Q4 25
Estimate
-$0.19
Actual
-$0.20
Surprise
-5.04%
Jupiter Neurosciences, Inc. Common Stock
Report Date
Apr 01, 2026 For Q4 25
Estimate
-$0.07
Actual
-$0.06
Surprise
+6.16%
Scienture Holdings, Inc. Common Stock
Report Date
Mar 30, 2026 For Q4 25
Estimate
-$0.28
Actual
-$0.11
Surprise
+61.48%
FAQ
What were Indivior Pharmaceuticals, Inc. Common Stock's earnings and revenue for the latest quarter Q4 2025?
For Q4 2025, Indivior Pharmaceuticals, Inc. Common Stock reported EPS of $0.82, beating estimates by 19.27%, and revenue of $358.00M, 14.84% above expectations.
How did the market react to Indivior Pharmaceuticals, Inc. Common Stock's Q4 2025 earnings?
The stock price moved up 0.24%, changed from $33.63 before the earnings release to $33.71 the day after.
When is Indivior Pharmaceuticals, Inc. Common Stock expected to report next?
The next earning report is scheduled for Apr 23, 2026.
What are the forecasts for Indivior Pharmaceuticals, Inc. Common Stock's next earnings report?
Based on 5
analysts, Indivior Pharmaceuticals, Inc. Common Stock is expected to report EPS of $0.66 and revenue of $278.09M for Q1 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement